Panacea Biotec Secures ₹78 Crore UNICEF Order for Oral Polio Vaccine Supply in 2028

BY ADMIN • FILED 05 Aug 2026, 10:35 AM

Panacea Biotec Limited (NSE: PANACEABIO | BSE: 531349) has received a significant order from the United Nations International Children’s Emergency Fund (UNICEF) for the supply of bivalent Oral Polio Vaccine (bOPV) valued at approximately US$8.205 million (around ₹78.24 crore) for the Calendar Year 2028.

The latest award strengthens Panacea Biotec’s long-standing partnership with UNICEF and reinforces the company’s position as a global supplier of life-saving vaccines.

UNICEF Awards ₹78 Crore Vaccine Supply Contract

The company informed the stock exchanges that it has received a Letter of Award from UNICEF for supplying bivalent Oral Polio Vaccine (bOPV) in 10-dose and 20-dose presentations during Calendar Year 2028.

Order Highlights

Customer: United Nations International Children’s Emergency Fund (UNICEF)
Product: Bivalent Oral Polio Vaccine (bOPV)
Order Value: US$8.205 million (approximately ₹78.24 crore)
Execution Period: Calendar Year 2028
Nature of Order: International vaccine supply contract

The award was received on August 4, 2026 under the existing long-term supply arrangement between the company and UNICEF.

Part of Existing Long-Term Agreement

This latest order is a continuation of the Long-Term Agreement (LTA) that Panacea Biotec signed with UNICEF in 2025.

Earlier, the company had announced that it secured a long-term contract covering the supply of bOPV from April 1, 2026, to March 31, 2030.

The initial allocation covered vaccine supplies for:

Q2 Calendar Year 2026
Calendar Year 2027

The newly awarded contract now extends supplies for Calendar Year 2028, highlighting UNICEF’s continued confidence in Panacea Biotec’s manufacturing capabilities and product quality.

Strengthening Global Vaccine Presence

UNICEF is one of the world’s largest vaccine procurement agencies, supplying vaccines to immunization programs across numerous countries.

Winning repeat orders from UNICEF demonstrates:

Compliance with stringent international quality standards.
Strong manufacturing and supply capabilities.
Continued participation in global public health initiatives.
Stable international business opportunities.

No Related Party Interest

Panacea Biotec clarified that:

The order has been awarded by an international organization.
There is no promoter or related party interest in the awarding entity.
The transaction is not a related-party transaction.

Positive for the Company

The latest award provides several positives for Panacea Biotec:

Strengthens revenue visibility for future years.
Reinforces its position in the global vaccine supply chain.
Enhances credibility through continued association with UNICEF.
Supports long-term growth in its vaccine business.

International procurement contracts from organizations such as UNICEF are generally considered an important validation of a vaccine manufacturer’s quality, production capacity, and regulatory compliance